Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805)

The oral fluoropyrimidine, S‐1, combined with or without gemcitabine is considered to be a promising agent for treating advanced biliary tract cancer; gemcitabine plus cisplatin is the current standard regimen. This randomized phase II trial was designed to evaluate the safety and efficacy of two re...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Morizane, Chigusa, Okusaka, Takuji, Mizusawa, Junki, Takashima, Atsuo, Ueno, Makoto, Ikeda, Masafumi, Hamamoto, Yasuo, Ishii, Hiroshi, Boku, Narikazu, Furuse, Junji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2013
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657216/
https://ncbi.nlm.nih.gov/pubmed/23763511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12218
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia